Sabine Mueller

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/4048735/sabine-mueller-publications-by-year.pdf

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

66 4,591 41 122 h-index g-index citations papers 5,962 127 5.1 5.57 L-index avg, IF ext. citations ext. papers

#	Paper	IF	Citations
122	Imipridones affect tumor bioenergetics and promote cell lineage differentiation in diffuse midline gliomas <i>Neuro-Oncology</i> , 2022 ,	1	2
121	Serial H3K27M cell-free tumor DNA (cf-tDNA) tracking predicts ONC201 treatment response and progression in diffuse midline glioma <i>Neuro-Oncology</i> , 2022 ,	1	3
120	Neurologic complications in the treatment of childhood malignancies 2022 , 433-462		
119	DIPG-07. Preclinical and case study results underpinning the phase II clinical trial testing the combination of ONC201 and paxalisib for the treatment of patients with diffuse midline glioma (NCT05009992). <i>Neuro-Oncology</i> , 2022 , 24, i18-i19	1	
118	RARE-13. Clinical management and functional and survival outcomes in pediatric craniopharyngioma, a patient and family perspective. <i>Neuro-Oncology</i> , 2022 , 24, i12-i12	1	
117	LGG-52. Volumetry-based response characterization of recurrent pediatric low-grade gliomas in PNOC clinical Neuro-oncology trials. <i>Neuro-Oncology</i> , 2022 , 24, i100-i100	1	
116	DIPG-31. Prognostic and predictive biomarkers of response in children and young adults with H3K27M-altered diffuse intrinsic pontine glioma: results from a multi-center, interventional clinical trial (PNOC003). <i>Neuro-Oncology</i> , 2022 , 24, i25-i25	1	
115	NURS-02. Incorporating Nurses and Advanced Practice Providers into Clinical Trial Consortiums; results of a multi-institutional survey from the Pacific Pediatric Neuro-Oncology Consortium (PNOC). <i>Neuro-Oncology</i> , 2022 , 24, i146-i146	1	
114	RARE-17. Multi-institutional craniopharyngioma cohort highlights need for more comprehensive data collection on comorbidities and quality of life. <i>Neuro-Oncology</i> , 2022 , 24, i13-i13	1	
113	EPCT-08. Disease-specific working groups within the Pacific Pediatric Neuro-Oncology Consortium (PNOC) and Children Brain Tumor Network (CBTN) facilitate multi-disciplinary collaboration and translation of innovative strategies in pediatric neuro-oncology. <i>Neuro-Oncology</i> , 2022 , 24, i37-i37	1	
112	DIPG-47. TSO500ctDNA sequencing reveals oncogenic mutations and copy number variations in the liquid biome of children with diffuse midline glioma. <i>Neuro-Oncology</i> , 2022 , 24, i29-i29	1	
111	Intracranial mesenchymal tumors with FET-CREB fusion are composed of at least two epigenetic subgroups distinct from meningioma and extracranial sarcomas. <i>Brain Pathology</i> , 2021 , e13037	6	О
110	Preclinical and clinical evaluation of German-sourced ONC201 for the treatment of H3K27M-mutant diffuse intrinsic pontine glioma <i>Neuro-Oncology Advances</i> , 2021 , 3, vdab169	0.9	2
109	Pilot Study of Hyperpolarized C Metabolic Imaging in Pediatric Patients with Diffuse Intrinsic Pontine Glioma and Other CNS Cancers. <i>American Journal of Neuroradiology</i> , 2021 , 42, 178-184	4.4	4
108	Standardization of the liquid biopsy for pediatric diffuse midline glioma using ddPCR. <i>Scientific Reports</i> , 2021 , 11, 5098	4.9	7
107	Relationship between 7T MR-angiography features of vascular injury and cognitive decline in young brain tumor patients treated with radiation therapy. <i>Journal of Neuro-Oncology</i> , 2021 , 153, 143-152	4.8	1
106	Multi-institutional analysis of treatment modalities in basal ganglia and thalamic germinoma. <i>Pediatric Blood and Cancer</i> , 2021 , 68, e29172	3	1

(2020-2021)

105	EPCT-02. COMPARISON OF TARGETED AGENTS RECOMMENDED BY THE CNS-TAP TOOL TO THOSE SELECTED BY A TUMOR BOARD IN A MOLECULARLY-DRIVEN DIPG CLINICAL TRIAL. <i>Neuro-Oncology</i> , 2021 , 23, i46-i46	1	78
104	EMBR-03. PINEOBLASTOMA: A POOLED OUTCOME STUDY OF NORTH AMERICAN AND AUSTRALIAN THERAPEUTIC DATA. <i>Neuro-Oncology</i> , 2021 , 23, i6-i6	1	78
103	Radiation in Combination With Targeted Agents and Immunotherapies for Pediatric Central Nervous System Tumors - Progress, Opportunities, and Challenges. <i>Frontiers in Oncology</i> , 2021 , 11, 6745	5 9 8	4
102	Rate of radiation-induced microbleed formation on 7T MRI relates to cognitive impairment in young patients treated with radiation therapy for a brain tumor. <i>Radiotherapy and Oncology</i> , 2021 , 154, 145-153	5.3	3
101	Mechanisms of imipridones in targeting mitochondrial metabolism in cancer cells. <i>Neuro-Oncology</i> , 2021 , 23, 542-556	1	11
100	Optimal therapeutic targeting by HDAC inhibition in biopsy-derived treatment-nalle diffuse midline glioma models. <i>Neuro-Oncology</i> , 2021 , 23, 376-386	1	10
99	Topographic correlates of driver mutations and endogenous gene expression in pediatric diffuse midline gliomas and hemispheric high-grade gliomas. <i>Scientific Reports</i> , 2021 , 11, 14377	4.9	
98	Repurposing vandetanib plus everolimus for the treatment of ACVR1-mutant diffuse intrinsic pontine glioma. <i>Cancer Discovery</i> , 2021 ,	24.4	2
97	Diffuse hemispheric glioma, H3 G34-mutant: Genomic landscape of a new tumor entity and prospects for targeted therapy. <i>Neuro-Oncology</i> , 2021 , 23, 1974-1976	1	1
96	Response to Karajannis et al. <i>Neuro-Oncology Practice</i> , 2020 , 7, 571	2.2	
96 95	Response to Karajannis et al. <i>Neuro-Oncology Practice</i> , 2020 , 7, 571 Response assessment in paediatric high-grade glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group. <i>Lancet Oncology, The</i> , 2020 , 21, e317		31
	Response assessment in paediatric high-grade glioma: recommendations from the Response		31
95	Response assessment in paediatric high-grade glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group. <i>Lancet Oncology, The</i> , 2020 , 21, e317	'-ê3 7 9	31 4 5
95	Response assessment in paediatric high-grade glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group. <i>Lancet Oncology, The</i> , 2020 , 21, e317 Neurocognitive Outcomes in Children with Brain Tumors. <i>Seminars in Neurology</i> , 2020 , 40, 315-321 Harmonization of postmortem donations for pediatric brain tumors and molecular characterization	7- 217 9	4
95 94 93	Response assessment in paediatric high-grade glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group. <i>Lancet Oncology, The</i> , 2020 , 21, e317 Neurocognitive Outcomes in Children with Brain Tumors. <i>Seminars in Neurology</i> , 2020 , 40, 315-321 Harmonization of postmortem donations for pediatric brain tumors and molecular characterization of diffuse midline gliomas. <i>Scientific Reports</i> , 2020 , 10, 10954 Pediatric hemispheric high-grade glioma: targeting the future. <i>Cancer and Metastasis Reviews</i> , 2020 ,	2- 63 79 3.2 4.9 9.6	4 5
95 94 93 92	Response assessment in paediatric high-grade glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group. <i>Lancet Oncology, The</i> , 2020 , 21, e317 Neurocognitive Outcomes in Children with Brain Tumors. <i>Seminars in Neurology</i> , 2020 , 40, 315-321 Harmonization of postmortem donations for pediatric brain tumors and molecular characterization of diffuse midline gliomas. <i>Scientific Reports</i> , 2020 , 10, 10954 Pediatric hemispheric high-grade glioma: targeting the future. <i>Cancer and Metastasis Reviews</i> , 2020 , 39, 245-260 Locoregionally administered B7-H3-targeted CAR T cells for treatment of atypical	2- 63 79 3.2 4.9 9.6	4 5 16
95 94 93 92 91	Response assessment in paediatric high-grade glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group. <i>Lancet Oncology, The</i> , 2020 , 21, e317 Neurocognitive Outcomes in Children with Brain Tumors. <i>Seminars in Neurology</i> , 2020 , 40, 315-321 Harmonization of postmortem donations for pediatric brain tumors and molecular characterization of diffuse midline gliomas. <i>Scientific Reports</i> , 2020 , 10, 10954 Pediatric hemispheric high-grade glioma: targeting the future. <i>Cancer and Metastasis Reviews</i> , 2020 , 39, 245-260 Locoregionally administered B7-H3-targeted CAR T cells for treatment of atypical teratoid/rhabdoid tumors. <i>Nature Medicine</i> , 2020 , 26, 712-719 Mass cytometry detects H3.3K27M-specific vaccine responses in diffuse midline glioma. <i>Journal of</i>	2- 63 79 3.2 4.9 9.6	4 5 16 74

87	MODL-26. CHILDREN® BRAIN TUMOR NETWORK: ACCELERATING RESEARCH THROUGH COLLABORATION AND OPEN-SCIENCE. <i>Neuro-Oncology</i> , 2020 , 22, iii416-iii416	1	78
86	GCT-23. MULTI-INSTITUTIONAL ANALYSIS OF TREATMENT MODALITIES IN BASAL GANGLIA AND THALAMIC GERMINOMA. <i>Neuro-Oncology</i> , 2020 , 22, iii332-iii332	1	78
85	Introduction. Pediatric brain tumor. Neurosurgical Focus, 2020, 48, E1	4.2	
84	NFB-17. MEK INHIBITOR BINIMETINIB SHOWS CLINICAL ACTIVITY IN CHILDREN WITH NEUROFIBROMATOSIS TYPE 1- ASSOCIATED PLEXIFORM NEUROFIBROMAS: A REPORT FROM PNOC AND THE NF CLINICAL TRIALS CONSORTIUM. <i>Neuro-Oncology</i> , 2020 , 22, iii420-iii421	1	5
83	Stroke impact on mortality and psychologic morbidity within the Childhood Cancer Survivor Study. <i>Cancer</i> , 2020 , 126, 1051-1059	6.4	5
82	Advances in Targeted Therapies for Pediatric Brain Tumors. <i>Current Treatment Options in Neurology</i> , 2020 , 22, 1	4.4	5
81	Response to Letter by Walker et al. Neuro-Oncology Practice, 2020, 7, 574-575	2.2	
80	Opportunities for the treatment of NF1-associated low-grade gliomas: how to decide on the best treatment options for patients?. <i>Neuro-Oncology</i> , 2020 , 22, 1415-1416	1	O
79	Comprehensive analysis of diverse low-grade neuroepithelial tumors with FGFR1 alterations reveals a distinct molecular signature of rosette-forming glioneuronal tumor. <i>Acta Neuropathologica Communications</i> , 2020 , 8, 151	7:3	17
78	Diffuse midline glioma: review of epigenetics. <i>Journal of Neuro-Oncology</i> , 2020 , 150, 27-34	4.8	11
77	Neuro-Oncology Practice Clinical Debate: targeted therapy vs conventional chemotherapy in pediatric low-grade glioma. <i>Neuro-Oncology Practice</i> , 2020 , 7, 4-10	2.2	6
76	Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201. <i>Journal of Neuro-Oncology</i> , 2019 , 145, 97-105	4.8	63
75	Brainstem Injury in Pediatric Patients Receiving Posterior Fossa Photon Radiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019 , 105, 1034-1042	4	4
74	Recurrent non-canonical histone H3 mutations in spinal cord diffuse gliomas. <i>Acta Neuropathologica</i> , 2019 , 138, 877-881	14.3	12
73	A systematic review and meta-analysis of outcomes in pediatric, recurrent ependymoma. <i>Journal of Neuro-Oncology</i> , 2019 , 144, 445-452	4.8	10
72	Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids. <i>Journal of Visualized Experiments</i> , 2019 ,	1.6	3
71	Oncolytic Measles Virotherapy and Opposition to Measles Vaccination. <i>Mayo Clinic Proceedings</i> , 2019 , 94, 1834-1839	6.4	4
70	HGG-15. SUCCESSFUL TREATMENT OF AN NTRK-FUSION POSITIVE INFANTILE GLIOBLASTOMA WITH LAROTRECTINIB, A TARGETED TRK INHIBITOR. <i>Neuro-Oncology</i> , 2019 , 21, ii89-ii90	1	3

(2018-2019)

69	HGG-24. COMPREHENSIVE GENOMIC ANALYSIS OF PEDIATRIC GLIOMAS UNCOVERS NOVEL MUTATIONS IN HISTONE-ENCODING GENES. <i>Neuro-Oncology</i> , 2019 , 21, ii91-ii92	1	78
68	IMMU-18. TARGETING H3.3 K27M MUTATION AS A SHARED NEOANTIGEN IN HLA-A*0201+ PATIENTS WITH DIFFUSE MIDLINE GLIOMAS IDEVELOPMENT OF A NOVEL MASS CYTOMETRY-BASED MONITORING OF VACCINE-REACTIVE, EPITOPE-SPECIFIC CD8+ T CELL	1	1
67	GENE-20. MULTI-GENE MUTATION PROFILING OF PEDIATRIC MIDLINE GLIOMAS USING PATIENT LIQUID BIOPSY. <i>Neuro-Oncology</i> , 2019 , 21, ii85-ii85	1	78
66	A pilot precision medicine trial for children with diffuse intrinsic pontine glioma-PNOC003: A report from the Pacific Pediatric Neuro-Oncology Consortium. <i>International Journal of Cancer</i> , 2019 , 145, 1889	-79501	45
65	Molecular profiling and targeted therapy in pediatric gliomas: review and consensus recommendations. <i>Neuro-Oncology</i> , 2019 , 21, 968-980	1	26
64	The genetic landscape of anaplastic pleomorphic xanthoastrocytoma. <i>Brain Pathology</i> , 2019 , 29, 85-96	6	54
63	Comparative Tumor RNA Sequencing Analysis for Difficult-to-Treat Pediatric and Young Adult Patients With Cancer. <i>JAMA Network Open</i> , 2019 , 2, e1913968	10.4	22
62	Diffusion Characteristics of Pediatric Diffuse Midline Gliomas with Histone H3-K27M Mutation Using Apparent Diffusion Coefficient Histogram Analysis. <i>American Journal of Neuroradiology</i> , 2019 , 40, 1804-1810	4.4	15
61	The genetic landscape of gliomas arising after therapeutic radiation. <i>Acta Neuropathologica</i> , 2019 , 137, 139-150	14.3	32
60	Deep sequencing of WNT-activated medulloblastomas reveals secondary SHH pathway activation. <i>Acta Neuropathologica</i> , 2018 , 135, 635-638	14.3	16
59	Prospective feasibility and safety assessment of surgical biopsy for patients with newly diagnosed diffuse intrinsic pontine glioma. <i>Neuro-Oncology</i> , 2018 , 20, 1547-1555	1	52
58	Large Vessel Arteriopathy After Cranial Radiation Therapy in Pediatric Brain Tumor Survivors. Journal of Child Neurology, 2018 , 33, 359-366	2.5	16
57	The genetic landscape of ganglioglioma. Acta Neuropathologica Communications, 2018, 6, 47	7.3	75
56	DIPG-76. PNOC-003: PRECISION MEDICINE TRIAL FOR CHILDREN WITH DIFFUSES INTRINSIC PONTINE GLIOMA: PRELIMINARY EXPERIENCE WITH MULTI-AGENT PERSONALIZED THERAPY RECOMMENDATIONS. <i>Neuro-Oncology</i> , 2018 , 20, i64-i64	1	2
55	Clinical Applications of Quantitative 3-Dimensional MRI Analysis for Pediatric Embryonal Brain Tumors. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018 , 102, 744-756	4	7
54	New therapeutic approaches for brainstem tumors: a comparison of delivery routes using nanoliposomal irinotecan in an animal model. <i>Journal of Neuro-Oncology</i> , 2018 , 136, 475-484	4.8	13
53	Novel and shared neoantigen derived from histone 3 variant H3.3K27M mutation for glioma T cell therapy. <i>Journal of Experimental Medicine</i> , 2018 , 215, 141-157	16.6	118
52	Survival outcomes in pediatric recurrent high-grade glioma: results of a 20-year systematic review and meta-analysis. <i>Journal of Neuro-Oncology</i> , 2018 , 137, 103-110	4.8	26

51	Pediatric low-grade gliomas: next biologically driven steps. <i>Neuro-Oncology</i> , 2018 , 20, 160-173	1	76
50	PDCT-04. PHASE 1 TRIAL OF WEE1 KINASE INHIBITOR AZD1775 COMBINED WITH RADIATION THERAPY FOR CHILDREN WITH NEWLY DIAGNOSED DIFFUSE INTRINSIC PONTINE GLIOMA: A REPORT FROM THE CHILDRENS ONCOLOGY GROUP PHASE 1 PILOT CONSORTIUM (ADVL1217).	1	2
49	TBIO-29. PedcBioPortal, A CANCER DATA VISUALIZATION TOOL FOR INTEGRATIVE PEDIATRIC CANCER ANALYSES. <i>Neuro-Oncology</i> , 2018 , 20, i186-i186	1	78
48	NIMG-67. CLINICAL APPLICATIONS OF QUANTITATIVE THREE-DIMENSIONAL MRI ANALYSIS FOR PEDIATRIC EMBRYONAL BRAIN TUMORS. <i>Neuro-Oncology</i> , 2018 , 20, vi191-vi191	1	78
47	DIPG-56. PRECLINICAL STUDIES OF DIANHYDROGALACTITOL (VAL-083) IN DIPG, AS SINGLE AGENT OR AS A COMBINATION WITH RADIATION OR AZD1775. <i>Neuro-Oncology</i> , 2018 , 20, i60-i60	1	78
46	HGG-38. DEVELOPMENT AND COMPREHENSIVE CHARACTERIZATION AND UTILIZATION OF PRECLINICAL MODELS OF PEDIATRIC HIGH GRADE GLIOMAS. <i>Neuro-Oncology</i> , 2018 , 20, i97-i97	1	78
45	TBIO-27. GABRIELLA MILLER KIDS FIRST DATA RESOURCE CENTER ADVANCING GENETIC RESEARCH IN CHILDHOOD CANCER AND STRUCTURAL BIRTH DEFECTS THROUGH LARGE SCALE INTEGRATED DATA-DRIVEN DISCOVERY AND CLOUD-BASED PLATFORMS FOR COLLABORATIVE	1	78
44	TBIO-28. DISEASEXPRESS, A CANCER DATA ANALYTICS AND VISUALIZATION TOOL FOR IDENTIFYING IMMUNOTHERAPEUTIC TARGETS IN PEDIATRIC BRAIN TUMORS AND OTHER CANCERS. <i>Neuro-Oncology</i> , 2018 , 20, i186-i186	1	78
43	DDIS-16. ONC201 IN COMBINATION WITH RADIATION EXHIBITS SYNERGISTIC EFFICACY IN HIGH GRADE GLIOMAS AND OTHER ADVANCED CANCERS. <i>Neuro-Oncology</i> , 2018 , 20, vi72-vi72	1	1
42	RTHP-21. CHARACTERIZATION OF RADIATION THERAPY EFFECTS ON CEREBRAL VASCULATURE IN PEDIATRIC BRAIN TUMOR SURVIVORS. <i>Neuro-Oncology</i> , 2018 , 20, vi229-vi229	1	2
41	EXTH-09. DIANHYDROGALACTITOL (VAL-083) HAS THE POTENTIAL TO OVERCOME MAJOR CHALLENGES IN THE TREATMENT OF DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG). Neuro-Oncology, 2018, 20, vi86-vi87	1	78
40	Early detection of recurrent medulloblastoma: the critical role of diffusion-weighted imaging. <i>Neuro-Oncology Practice</i> , 2018 , 5, 234-240	2.2	5
39	Clinically Relevant and Minimally Invasive Tumor Surveillance of Pediatric Diffuse Midline Gliomas Using Patient-Derived Liquid Biopsy. <i>Clinical Cancer Research</i> , 2018 , 24, 5850-5859	12.9	62
38	Reirradiation and PD-1 inhibition with nivolumab for the treatment of recurrent diffuse intrinsic pontine glioma: a single-institution experience. <i>Journal of Neuro-Oncology</i> , 2018 , 140, 629-638	4.8	22
37	Abnormal Morphology of Select Cortical and Subcortical Regions in Neurofibromatosis Type 1. <i>Radiology</i> , 2018 , 289, 499-508	20.5	5
36	Dual HDAC and PI3K Inhibition Abrogates NF B - and FOXM1-Mediated DNA Damage Response to Radiosensitize Pediatric High-Grade Gliomas. <i>Cancer Research</i> , 2018 , 78, 4007-4021	10.1	36
35	Evaluation of Pre-Hematopoietic Cell Transplantation (HCT) Brain MRI and Neurologic Complications of Pediatric Patients Undergoing HCT for Hematologic Malignancies. <i>Journal of Pediatric Oncology Nursing</i> , 2017 , 34, 65-73	2	
34	Imaging Characteristics of Pediatric Diffuse Midline Gliomas with Histone H3 K27M Mutation. <i>American Journal of Neuroradiology</i> , 2017 , 38, 795-800	4.4	90

33	Pediatric high-grade glioma: current molecular landscape and therapeutic approaches. <i>Journal of Neuro-Oncology</i> , 2017 , 134, 541-549	4.8	68
32	Case-based review: pediatric medulloblastoma. <i>Neuro-Oncology Practice</i> , 2017 , 4, 138-150	2.2	13
31	Therapeutic and Prognostic Implications of BRAF V600E in Pediatric Low-Grade Gliomas. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2934-2941	2.2	153
30	Targeted next-generation sequencing of pediatric neuro-oncology patients improves diagnosis, identifies pathogenic germline mutations, and directs targeted therapy. <i>Neuro-Oncology</i> , 2017 , 19, 699-	7 09	118
29	Pediatric high-grade glioma: biologically and clinically in need of new thinking. <i>Neuro-Oncology</i> , 2017 , 19, 153-161	1	125
28	Survival after chemotherapy and stem cell transplant followed by delayed craniospinal irradiation is comparable to upfront craniospinal irradiation in pediatric embryonal brain tumor patients. <i>Journal of Neuro-Oncology</i> , 2017 , 131, 359-368	4.8	9
27	GENE-43. LIQUID BIOPSY FOR MONITORING OF TUMOR RESPONSE IN CHILDREN WITH DIFFUSE MIDLINE GLIOMA. <i>Neuro-Oncology</i> , 2017 , 19, vi101-vi102	1	78
26	PDCT-19. Albafety study of vemurafenib, an oral inhibitor of brafv600e, in children with recurrent/refractory brafv600e mutant brain tumors: pnoc-002. Neuro-Oncology, 2017 , 19, vi188-vi188	1	5
25	Overcoming resistance to single-agent therapy for oncogenic gene fusions combinatorial targeting of MAPK and PI3K/mTOR signaling pathways. <i>Oncotarget</i> , 2017 , 8, 84697-84713	3.3	26
24	Pediatric low-grade gliomas: implications of the biologic era. <i>Neuro-Oncology</i> , 2017 , 19, 750-761	1	47
23	Presence of cerebral microbleeds is associated with worse executive function in pediatric brain tumor survivors. <i>Neuro-Oncology</i> , 2016 , 18, 1548-1558	1	28
22	Clinical trials in pediatric neuro-oncology: what is missing and how we can improve. <i>CNS Oncology</i> , 2016 , 5, 233-9	4	6
21	Late Effects of Treatment of Pediatric Central Nervous System Tumors. <i>Journal of Child Neurology</i> , 2016 , 31, 237-54	2.5	61
20	Survival advantage combining a BRAF inhibitor and radiation in BRAF V600E-mutant glioma. <i>Journal of Neuro-Oncology</i> , 2016 , 126, 385-93	4.8	25
19	MYB-QKI rearrangements in angiocentric glioma drive tumorigenicity through a tripartite mechanism. <i>Nature Genetics</i> , 2016 , 48, 273-82	36.3	154
18	Inactivating MUTYH germline mutations in pediatric patients with high-grade midline gliomas. <i>Neuro-Oncology</i> , 2016 , 18, 752-3	1	13
17	Clinical outcome and prognostic factors for central neurocytoma: twenty year institutional experience. <i>Journal of Neuro-Oncology</i> , 2016 , 126, 193-200	4.8	31
16	RO-02CEREBRAL MICROBLEEDS ARE ASSOCIATED WITH WORSE EXECUTIVE FUNCTION IN PEDIATRIC BRAIN TUMOR SURVIVORS. <i>Neuro-Oncology</i> , 2016 , 18, iii159.2-iii159	1	19

15	IDH1 mutation can be present in diffuse astrocytomas and giant cell glioblastomas of young children under 10 years of age. <i>Acta Neuropathologica</i> , 2016 , 132, 153-5	14.3	18
14	Rates and characteristics of radiographically detected intracerebral cavernous malformations after cranial radiation therapy in pediatric cancer patients. <i>Journal of Child Neurology</i> , 2015 , 30, 842-849	2.5	26
13	Recurrent stroke in childhood cancer survivors. <i>Neurology</i> , 2015 , 85, 1056-64	6.5	32
12	EAG2 potassium channel with evolutionarily conserved function as a brain tumor target. <i>Nature Neuroscience</i> , 2015 , 18, 1236-46	25.5	56
11	WEE1 Kinase As a Target for Cancer Therapy. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3485-7	2.2	37
10	Pharmacologic inhibition of histone demethylation as a therapy for pediatric brainstem glioma. <i>Nature Medicine</i> , 2014 , 20, 1394-6	50.5	317
9	Targeting Wee1 for the treatment of pediatric high-grade gliomas. <i>Neuro-Oncology</i> , 2014 , 16, 352-60	1	74
8	Feasibility, safety, and indications for surgical biopsy of intrinsic brainstem tumors in children. <i>Childts Nervous System</i> , 2013 , 29, 1313-9	1.7	47
7	Risk of first and recurrent stroke in childhood cancer survivors treated with cranial and cervical radiation therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013 , 86, 643-8	4	44
6	Radiation, atherosclerotic risk factors, and stroke risk in survivors of pediatric cancer: a report from the Childhood Cancer Survivor Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013 , 86, 649-55	4	105
5	The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression. <i>Genes and Development</i> , 2013 , 27, 985-90	12.6	443
4	Poly (ADP-Ribose) polymerase inhibitor MK-4827 together with radiation as a novel therapy for metastatic neuroblastoma. <i>Anticancer Research</i> , 2013 , 33, 755-62	2.3	20
3	PTEN promoter methylation and activation of the PI3K/Akt/mTOR pathway in pediatric gliomas and influence on clinical outcome. <i>Neuro-Oncology</i> , 2012 , 14, 1146-52	1	69
2	Cooperation of the HDAC inhibitor vorinostat and radiation in metastatic neuroblastoma: efficacy and underlying mechanisms. <i>Cancer Letters</i> , 2011 , 306, 223-9	9.9	54
1	Neuroblastoma: biology and staging. <i>Current Oncology Reports</i> , 2009 , 11, 431-8	6.3	74